Author: Zacks Small Cap Research

138394041400 / 402 POSTS
By Lisa ThompsonNASDAQ:CSSEToday CSSE (NASDAQ:CSSE) announced its acquisition of Screen Media, a NYC based company comprised of a film and TV content library, a content distributor, and a streaming platform. This gem was a distressed purchase for $5 ...
By Brian Marckx, CFANASDAQ:GNMXQ3 Results / Operational UpdateAevi (NASDAQ:GNMX) reported financial results for their third quarter on November 2nd.  The operational update mostly relates to timelines of the various ongoing studies – while this inclu ...
By Lisa ThompsonNASDAQ:OIIMO2Micro (NASDAQ:OIIM) reported Q3 2017 revenues of $15.5 million slightly higher than expected and up 7% from last year. Guidance for revenue for the fourth quarter is sequentially flat, plus or minus five percent which, at ...
By Brian Marckx, CFAOTC:SMLRQ3 2017 Results:  Record Revenue, Operating Income. OpEx at All-Time Low. Modeling Net Income in Q4…Semler (OTC:SMLR) reported financial results for their third quarter ending September 30th.  Results were extraordinarily ...
By David Bautz, PhDNASDAQ:MNOVBusiness UpdateSPRINT-MS Trial Achieves Primary EndpointsOn October 30, 2017, MediciNova, Inc. (NASDAQ:MNOV) announced positive top-line results from the SPRINT-MS Phase 2b clinical trial of MN-166 (ibudilast) in patient ...
By Brian Marckx, CFANASDAQ:CTSOAdd’l Clinical Evidence Indicates CytoSorb Associated w/ Improved Outcomes in Sepsis, Cardiac SurgeryCytoSorbents (NASDAQ:CTSO) recently announced the publication of two unrelated studies (one in sepsis, the other in ca ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateFull Data Set for VK2809 in Diet-Induced NASH Model Presented at AASLDOn October 24, 2017, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the presentation of results from a study of VK2809 in an in vivo ...
By John Vandermosten, CFANASDAQ:EGLTWe are initiating coverage of Egalet Corp. (NASDAQ:EGLT) with a $6.00 price target based on our estimates for growth of three products currently being commercialized in the United States.  Egalet has developed a th ...
By Brian Marckx, CFANASDAQ:BMRA Q1 2018 Results: Fairly Solid, Timing Issue Should Benefit Q2. Looking Forward to Details on H. Pylori Test... Biomerica (NASDAQ:BMRA) reported financial results for their fiscal 2018 first quarter ending August 3 ...
By David Bautz, PhDNASDAQ:BCLIBusiness UpdatePhase 3 Trial UnderwayOn October 16, 2017, BrainStorm (NASDAQ:BCLI) announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotro ...
138394041400 / 402 POSTS